Effect of Momordica charantia L. supplementation on patients with Diabetes mellitus: A systematic review
Keywords:Momordica charantia L; Insulin resistance; Diabetes; Popular medicine.
Diabetes mellitus (DM) is a chronic, multifactorial disease that comprises a heterogeneous group of metabolic disorders, being classified as a public health problem that is difficult to control. The use of medicinal plants in disease control has been gaining a lot of visibility due to therapy, easy access and successful clinical cases. Some plant species are used to suppress symptoms caused by diabetes mellitus in association or not with traditional medicine, among them, the São Caetano melón (Momordica charantia L.). The current review aimed to analyze the main researches on the use of Momordica charantia L. in the treatment of diabetes mellitus. This is a systematic review based on original articles published in English that were selected from the databases Pubmed, Cochrane Library, LILACS and ScienceDirect. After applying the inclusion and exclusion criteria, a total of 07 articles were finally selected for the research, where it was observed that M. charantia L. proved to be an alternative with a potential antidiabetic effect in the control of diabetes mellitus.
Alvarenga, C. F., de Lima, K. M. N., Mollica, L. R., Azeredo, L. O., & de Carvalho, C. (2017). Uso de plantas medicinais para o tratamento do diabetes mellitus no Vale do Paraíba-SP. Revista Ciência e Saúde On-line, 2(2).
Baade, R. T. W., & Bueno, E. (2016). Coconstrução da autonomia do cuidado da pessoa com diabetes. Interface-Comunicação, Saúde, Educação, 20, 941-951.
Bakare, R. I., Magbagbeola, O. A., & Okunowo, O. W. (2010). Nutritional and chemical evaluation of Momordica charantia. Journal of Medicinal Plants Research, 4(21), 2189-2193.
Basch, E., Gabardi, S., & Ulbricht, C. (2003). Bitter melon (Momordica charantia): a review of efficacy and safety. American Journal of Health-System Pharmacy, 60(4), 356-359.
Bhutkar, M. A., & Bhise, S. B. (2012). In vitro assay of alpha amylase inhibitory activity of some indigenous plants. Int. J. Chem. Sci, 10(1), 457-462.
Brasil. Política nacional de plantas medicinais e fitoterápicos. Ministério da Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos, Departamento de Assistência Farmacêutica. Brasília, 2006.
Dans, A. M. L., Villarruz, M. V. C., Jimeno, C. A., Javelosa, M. A. U., Chua, J., Bautista, R., & Velez, G. G. B. (2007). The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. Journal of clinical epidemiology, 60(6), 554-559.
Fernandes, N. P., Lagishetty, C. V., Panda, V. S., & Naik, S. R. (2007). An experimental evaluation of the antidiabetic and antilipidemic properties of a standardized Momordica charantia fruit extract. BMC complementary and alternative medicine, 7(1), 1-8.
Fuangchan, A., Sonthisombat, P., Seubnukarn, T., Chanouan, R., Chotchaisuwat, P., Sirigulsatien, V., ... & Haines, S. T. (2011). Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients. Journal of ethnopharmacology, 134(2), 422-428.
Glovaci, D., Fan, W., & Wong, N. D. (2019). Epidemiology of diabetes mellitus and cardiovascular disease. Current cardiology reports, 21(4), 1-8.
Guimarães, R. A., Morais Neto, O. L. D., Souza, M. R. D., Cortez-Escalante, J. J., Santos, T. A. D. P., Rosso, C. F. W., ... & Maia, L. G. (2019). Epidemiology of Self-Reported Diabetes Mellitus in the State of Maranhão, Northeastern Brazil: Results of the National Health Survey, 2013. International journal of environmental research and public health, 16(1), 47.
Hafizur, R. M., Kabir, N., & Chishti, S. (2011). Modulation of pancreatic β-cells in neonatally streptozotocin-induced type 2 diabetic rats by the ethanolic extract of Momordica charantia fruit pulp. Natural Product Research, 25(4), 353-367.
Jia, S., Shen, M., Zhang, F., & Xie, J. (2017). Recent advances in Momordica charantia: functional components and biological activities. International journal of molecular sciences, 18(12), 2555.
Jiang, S., Xu, L., Xu, Y., Guo, Y., Wei, L., Li, X., & Song, W. (2020). Antidiabetic effect of Momordica charantia saponins in rats induced by high-fat diet combined with STZ. Electronic Journal of Biotechnology, 43, 41-47.
Kumari, S., Dash, I., & Behera, K. K. (2018). Therapeutic Effect of Momordica charantia on Blood Glucose, Lipid Profile and Oxidative Stress in Type 2 Diabetes Mellitus Patients: A Randomised Controlled Trial. Journal of Clinical & Diagnostic Research, 12(9).
Kwatra, D., Dandawate, P., Padhye, S., & Anant, S. (2016). Bitter melon as a therapy for diabetes, inflammation, and cancer: a panacea?. Current Pharmacology Reports, 2(1), 34-44.
Leatherdale, B. A., Panesar, R. K., Singh, G., Atkins, T. W., Bailey, C. J., & Bignell, A. H. (1981). Improvement in glucose tolerance due to Momordica charantia (karela). British medical jornal. 282(6279), 1823-1824.
Malinoski, B., Cain, J. P., Amaral, L. A., Antonovicz, S., Bernardi, L. (2020). Modelos experimentais para estudos em nutrição: hipertensão arterial e diabetes mellitus. Visão Acadêmica, Curitiba. 17(4).
Percin, P. S., Inanli, O., Karakaya, S. (2018). In vitro α-amylase and α-glucosidase inhibitory activities of bitter melon (Momordica charantia) with different stage of maturity. International Journal of Nutrition and Food Engineering. 12(1).
Pereira, F. K., & Abi, R. C. D. (2019). Complicações do Diabetes Mellitus. International Journal of Health Management, 5(1).
Rahman, I. U., Khan, R. U., Rahman, K. U., & Bashir, M. (2015). Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients. Nutrition journal, 14(1), 1-7.
Silva, J. C., Heinen, A., Scheidt, M. B., Marcondes, M. A. D. O., & Bertini, A. M. (2007). Tratamento do diabetes mellitus gestacional com glibenclamida: fatores de sucesso e resultados perinatais. Revista Brasileira de Ginecologia e Obstetrícia, 29(11), 555-560.
Tresvenzol, L. M. F., Paula, J. R. D., Ricardo, A. F., Ferreira, H. D., & Zatta, D. T. (2006). Estudo sobre o comércio informal de plantas medicinais em Goiânia e cidades vizinhas. Revista Eletrônica de Farmácia. 3(1), 23-8.
Vinayagam, R., Jayachandran, M., & Xu, B. (2016). Antidiabetic effects of simple phenolic acids: a comprehensive review. Phytotherapy research, 30(2), 184-199.
Walters, W., Decker-Walters, D. S. (1988). Notes on Economic plants. Econ. Botan. 42(2), 286-292.
Wang, H. Y., Kan, W. C., Cheng, T. J., Yu, S. H., Chang, L. H., & Chuu, J. J. (2014). Differential anti-diabetic effects and mechanism of action of charantin-rich extract of Taiwanese Momordica charantia between type 1 and type 2 diabetic mice. Food and Chemical Toxicology, 69, 347-356.
Wu, S. J., & Ng, L. T. (2008). Antioxidant and free radical scavenging activities of wild bitter melon (Momordica charantia Linn. var. abbreviata Ser.) in Taiwan. LWT-Food Science and Technology, 41(2), 323-330.
Xu, X., Shan, B., Liao, C. H., Xie, J. H., Wen, P. W., & Shi, J. Y. (2015). Anti-diabetic properties of Momordica charantia L. polysaccharide in alloxan-induced diabetic mice. International journal of biological macromolecules, 81, 538-543.
Yang, S. J., Choi, J. M., Park, S. E., Rhee, E. J., Lee, W. Y., Oh, K. W., ... & Park, C. Y. (2015). Preventive effects of bitter melon (Momordica charantia) against insulin resistance and diabetes are associated with the inhibition of NF-κB and JNK pathways in high-fat-fed OLETF rats. The Journal of Nutritional Biochemistry, 26(3), 234-240.
How to Cite
Copyright (c) 2021 Edite Maria Morais do Nascimento; Gabriela Lima de Araujo; Bruna Emanuele Pereira Cardoso; Stéfany Rodrigues de Sousa Melo; Maiara Jaianne Bezerra Leal Rios; Paulo Víctor de Lima Sousa; Guida Graziela Santos Cardoso; Thaline Milany da Silva Dias; Jennifer Beatriz Silva Morais
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.